SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Thomas Andrew Garner has been appointed Chief Commercial Officer, effective today. Mr. Garner will spearhead ...

Acadia Pharmaceuticals has hired Big Pharma veteran Thomas Andrew Garner as its new chief commercial officer (CCO). The company is looking to consolidate its older drug, Nuplazid, while boosting its ...

Acadia Pharmaceuticals has shown significant financial improvement, reporting a profit of $82.7m in 2024, compared to a loss of $(107m) in 2023. The company's revenue growth is driven by NUPLAZID and ...

Acadia Pharmaceuticals (ACAD) Inc. announced it has entered into an exclusive worldwide license agreement with Saniona for the development and commercialization of SAN711, a first-in-class, highly ...